MDCK-MRP2 - Dkfz

226
Forschungsschwerpunkt D
Tumorimmunologie
[13] Bai, L., Beckhove, P., Feuerer, M., Umansky, V., *Solomayer,
E.F., *Diel, I.J. and Schirrmacher V.: Cognate interactions between
memory T cells and tumor antigen presenting dendritic
cells from bone marrow of breast cancer patients: bi-directional
cell stimulation survival and anti-tumor activity in vivo. Int. J.
Cancer, 103: 73-83 (2003)
[14] M. Lindner and V. Schirrmacher: Tumor cell dendritic cell fusion
for cancer immunotherapy: comparison of therapeutic efficiency
of polyethylen-glycol versus electro-fusion protocols. Eur.
J. Clin. Invest. 32: 207-217 (2002)
[15] Zeng J., Fournier, P. and Schirrmacher, V. Induction of interferon
a and TRAIL in human blood mononuclear cells by HN but
not F protein of Newcastle Disease Virus. Virology, 297:19-30,
2002.
[16] Washburn, B., Weigand, M.A., Grosse-Wilde A., Sprick,
M.R., Schirrmacher V. and Walczak H.: TNF-related apoptosisinducing
ligand mediates tumoricidal activity of human monocytes
stimulated by Newcastle Disease Virus. J. Immun., Feb. 15; 170
(4): 1814-1821 (2003).
[17] Zeng, J., Fournier, P., Schirrmacher, V.: stimulation of human
natural interferon-α response via paramyxo-virus hemagglutinin
lectin-cell interaction. J. Molec. Med., 80: 443-451 (2002).
[18] Fournier, P. , Zeng, J., *Von der Lieth, C.W., Washburn, B.,
Ahlert, T. and Schirrmacher V. Importance of serine 200 for
functional activities of the hemagglutinin-neuraminidase protein
of Newcastle Disease Virus. Int. J. Oncol., in press.
[19] Bai, L., *Koopmann, J., Fiola, C., Fournier, P., Schirrmacher
V.: Dendritic cells pulsed with viral oncolysates potently stimulate
autologous T cells from cancer patients. Int. J. Oncol. Oct. 21:
685-694 (2002).
[20] Fournier P., J.Y. Zeng and V. Schirrmacher: Two ways to induce
innate immune responses in human PBMCs: Paracrine stimulation
of IFN-a responses by viral protein or dsRNA. Int. J.
Oncol. 23: 673-680 (2003)
[21] *Steiner, H.H., *Bonsanto, M.M., Beckhove, P., Brysch, M.,
*Schuele-Freyer, R., *Geletneky, K., *Kremer, P., *Golamrheza,
R., *Bauer H., *Kunze S., Schirrmacher, V., *Herold-Mende C.:
Anti-tumor vaccination of patients with glioblastoma multiforme in
a case-control study: Feasibility, safety and clinical benefit. Submitted.
[22] Washburn, B. and Schirrmacher V.: Human tumor cell infection
by Newcastle Disease Virus leads up to upregulation of HLA
and cell adhesion molecules and to induction of interferons,
chemokines and finally apoptosis. Int. J. Oncol. 21: 85-93, 2002.
[23] Schirrmacher, V. Feuerer, M., Beckhove, P., *Ahlert, T.,
Umansky, V.: T cell memory, anergy and immunotherapy in breast
cancer. J. Mammary Gland Biol. Neoplasia, Apr. 7 (2): 201-208
(2002).
[24] Schirrmacher V.: Anti-tumor immune memory and its activation
for control of residual tumor cells and improvement of
patient survival. In: “Virus therapy of human cancers“. (Sinkovics
J., Horvath J. eds., Marcel Decker Monograph in press.)
[25] Schirrmacher V.: Improvements of survival in nine phase II
clinical studies with different types of cancer upon anti-tumor
vaccination with an autologous tumor cell vaccine modified by virus
infection to introduce danger signals. In: New trends in Cancer
for the 21st Century. (Editors A. Llombart-Bosch and
Vincente Felipo) Advances in Experimental Medicine and Biology,
Volume 532, pp 175-193, Publishers Kluwer Academic (Plenum
Publishers. (2003).
[26] Chlichlia K., *Bahgat M., *Ruppel, A., Schirrmacher V.: DNA
vaccination with asparaginyl endopeptidase (Sm32) from the
parasite Schistosoma mansoni: anti-fecundity induced in mice.
Vaccine, 20: 439-447 (2002).
[27] Chlichlia, K., *Bahgat, M., Schirrmacher, V., *Ruppel A.:
Species-restricted antibody response against a DNA-construct
coding for aspartic proteinase from Schistosoma japonicum.
Parasitol. Res., 88: 368-375 (2002).
Abteilung D010
Zelluläre Immunologie
[28] *Bahgat, M., Chlichlia, K., Schirrmacher, V., *Ruppel A.: Antibodies
induced in mice by a DNA-construct coding for the elastase
of Schistosoma mansoni recognize the enzyme in secretions
and preacetabular glands of cercariae. Parasitol. 124: 301-306,
2002.
[29] Schirrmacher, V., Umansky V., Lindner, M., Müerköster, S.
and Rocha M.: Models for immunotherapy and cancer vaccines.
(In: The Cancer Handbook) Macmillan Publ. Ltd., M. Alison and G.
Nicolson, ed. Vol. 2 p 1055 (2002).
[30] Chlichlia, K., Los M., *Schulze-Osthoff, K., *Gazzolo, L.,
Schirrmacher V. and *Khazaie, K.: Redox Events in HTLV-1 Taxinduced
apoptotic T cell death. Forum Review Article. “Antioxidants
& Redox Signalling” Vol. 4, 3: 471-477 (2002).
[31] Schirrmacher V.:, Tumorimmunologie In: Grundlagen der
Komplementär-Onkologie. J. Beuth, Hrsg. Hippokrates, 37-44
(2002).
[32] Schirrmacher V.: Tumorvakzinierung und antikörpervermittelte
Immuntherapien. In: Grundlagen der Komplementär-Onkologie.
J. Beuth, Hrsg. Hippokrates, 235-244 (2002).
[33] Schirrmacher V.: Möglichkeiten einer T-Zell-vermittelten
Immuntherapie bei Hirntumoren. “Brainstorm“ (9), 2003.
Die Rolle von Zelladhäsion und Migration bei
Lymphozyten-Homing und Tumor-
Metastasierung.
P. Altevogt, S. Schlich, P. Gutwein
In Kollaboration mit Mina Fogel, Kaplan Hospital Rehovot, Israel;
Vance Lemmon, Universität Miami, Florida, USA; Glen Kristansen
Charité, Berlin.; Jörg Reichrath, Dermatologische Klinik Universität
des Saarlandes, Homburg; Brigitte Schmitz, Universität
Bonn; Martin Deichmann, Dermatologische Klinik Universität
Heidelberg; Hanswalter Zentgraf, DKFZ; Lutz Edler, DKFZ.
DKFZ 2004: Wissenschaftlicher Ergebnisbericht 2002 - 2003
Tumorzellen benutzen für Tumormetastasierung und Invasion
ähnliche molekulare Mechanismen der Migration und
Proteolyse wie Immunzellen bei der Immunüberwachung
des Körpers. Wir untersuchen die Funktion des humanes
L1 Adhäsionsmoleküls und des CD24, eines Liganden für P-
Selektin, bei der Zellmigration und Adhäsion von Karzinomzellen.
Unser Hauptaugenmerk gilt der Funktion von L1
und seiner proteolytischen Spaltung durch die Metalloproteinase
ADAM10 bei Karzinomen der Eierstöcke und der
Gebärmutter.
Publikationen (* = externer Koautor)
[1] *Barth,T.F.E., *Rinaldi, N., *Brüderlein, S., *Mechtersheimer,
G., *Sträter,J., Altevogt, P., *Möller, P.: Mesothelial cells in suspension
expose an enriched integrin repertoire capable of capturing
soluble fibronectin and laminin. Cell Commun. Adhes. 9: 1-
14 (2002)
[2] Gutwein, P., Mechtersheimer,S., Riedle,S., Stoeck,A.,
Gast,D., Joumaa,S., *Zentgraf,H., Fogel,M. and Altevogt,P.:
ADAM10-mediated cleavage of L1 adhesion molecule at the cell
surface and in released membrane vesicles. FASEB J.17:292-4
(2003).
[3] *Fogel, M., Mechtersheimer, S., *Smirnov, A.,*Husar, M.,
*Abu-Dahi, A., *Tilgen, W., *Reichrath, J., *Georg, T., Altevogt
,P. and Gutwein, P.: L1 adhesion molecule (CD 171) in development
and progression of human malignant melanoma. Cancer
Lett.189:237-47. (2003)
[4] *Phong,M.-C., Gutwein,P., *Kadel,S. Hexel,K., Altevogt,P.,
*Linderkamp,O., and *Brenner,B.: Molecular mechanisms of Lselectin-induced
colocalization: rafts and shedding. BBRC ,
300:563-569 (2003)
[5] *Ohl, C., *Albach, C., Altevogt, P. and *Schmitz, B.: N-
Glycosylation patterns of HSA/CD24 from different cell lines and
brain homogenates: A comparison. Biochimie, 85:565-573 (2003)